دوشنبه , تیر ۶ ۱۴۰۱
آخرین خبرها

بایگانی/آرشیو برچسب ها : Molecular Docking

Design of novel derivatives of Ellagic acid

دکتر مهدی نباتی مدرس شیمی کنکور و دبیرستان متخصص شیمی آلی سنتز و فرمولاسیون دارو و طراحی دارو و محصولات آرایشی بهداشتی

Substitution of carbonyl group of ellagic acid with silanediol group for better inhibition of VEGFR-2 Kinase enzyme What is cancer? The major cause of death worldwide is cancer. Surgery, chemotherapeutic agents and radiation which are cancer therapy have not been much efficient in the reduction of cancer occurrence and raising …

بیشتر بخوانید »

Withaferin A (WIT) interaction with β–Tubulin

دکتر مهدی نباتی مدرس شیمی کنکور و دبیرستان متخصص شیمی آلی سنتز و فرمولاسیون دارو و طراحی دارو

Withaferin A (WIT) interaction with β–Tubulin Withaferin A (WIT) Withaferin A (WIT) is an important natural compound extracted from the Indian medicinal plant Withania somnifera. This plant has been used for over 3000 years in Unani Indian medical system. Also, its extracted medicinal compound has been in ayurvedic medicine and …

بیشتر بخوانید »

Irilone as a progesterone receptor (PR) effect supporter in endometrial and ovarian cancer cell lines

Dr. Mehdi Nabati Iranian Drug Designer

Irilone as a progesterone receptor (PR) effect supporter in endometrial and ovarian cancer cell lines   Estrogen and Progesterone receptors (ER, PR) are ligand-induced transcription factor members of the steroid hormone receptor (SR) subfamily of nuclear receptors. Those receptors and their corresponding steroid hormones (estradiol and progesterone) play their roles …

بیشتر بخوانید »

zotepine as an atypical antipsychotic antagonist

Physicochemical properties analysis and dopamine D2 receptor (D2R) docking of zotepine as an atypical antipsychotic antagonist

Zotepine as an atypical antipsychotic antagonist Schizophrenia is a chronic, critical condition characterized by collective psychotic signs and symptoms, exhibited as alterations in patient’s thoughts, perception and behavioral attributes. Schizophrenia is mostly accompanied by symptoms that are generally categorized into two major groups: 1: Positive symptoms including hallucinations (auditory, visual, …

بیشتر بخوانید »

Esketamine for Major Depressive Disorder (MDD) treatment

esketamine for Major Depressive Disorder (MDD) treatment

Esketamine for Major Depressive Disorder (MDD) treatment Major depressive disorder or MDD is a serious neurological condition that afflicts almost 300 million people around the world. Over the years, various classes of antidepressants have been developed. Although the efforts to manage MDD have been fruitful in many cases, still about …

بیشتر بخوانید »

Novel drugs for autism treatment

novel drugs based on zonisamide

Novel drugs for autism treatment Autism spectrum disorders (ASDs) are complex and prevalent neurodevelopmental disorders predominantly diagnosed through observation of a wide variety of atypical behavior, expressed by impairments in socialization, communication, thinking, interests, activities and cognitive skills as well as restricted and repetitive behavior. Autism is considered a heterogeneous …

بیشتر بخوانید »

Metoclopramide as a small molecule of dopamine D2 receptor

In Silico Study of Metoclopramide as A Small Molecule of Dopamine D2 Receptor

 Metoclopramide as a small molecule of dopamine D2 receptor Dopamine D2 receptor (D2R) has been constructed from various natural amino acids in humans that is encoded by DRD2 gene. This protein (D2R) is the most important receptor for many antipsychotic medicines. The D2R structure has been known using a radiolabeled …

بیشتر بخوانید »

Dr. Mehdi Nabati

Doctor Mehdi Nabati

Curriculum vitae *************************************** Mehdi Nabati Ph.D. of Organic Chemistry Date of Birth: 22/04/1988 Place of Birth: Maragheh, East Azarbaijan, Iran Marital Status: Single Mobile Number: +989011828140 E-mail: mnabati@ymail.com *************************************** EDUCATION AND RESEARCH Azarbaijan Shahid Madani University, Tabriz, Iran . Ph.D., Organic Chemistry, with Dr. Mehrdad Mahkam, Sept. 2012 – ۲۰۱۵ …

بیشتر بخوانید »